Who are Progesterone Lozenges's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vitamin D (Cholecalciferol ), Dehydroepiandrosterone (DHEA), Agonist GnRH; estradiol Valerate; progesterone, Vitamin D: liquid form, start monthly, Vitamin D: liquid form, start weekly, Vit D.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/progesterone-lozenges.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Progesterone Lozenges — Competitive Intelligence Brief

Progesterone Lozenges (Progesterone Lozenges) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Steroid hormone. Area: Reproductive Health / Endocrinology.

phase 3 Steroid hormone Progesterone receptor (PR) Reproductive Health / Endocrinology Biologic Live · refreshed every 30 min

Target snapshot

Progesterone Lozenges (Progesterone Lozenges) — Beth Israel Deaconess Medical Center. Progesterone acts as a steroid hormone that binds to progesterone receptors to modulate reproductive and metabolic processes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Progesterone Lozenges TARGET	Progesterone Lozenges	Beth Israel Deaconess Medical Center	phase 3	Steroid hormone	Progesterone receptor (PR)
Vitamin D (Cholecalciferol )	Vitamin D (Cholecalciferol )	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)
Dehydroepiandrosterone (DHEA)	Dehydroepiandrosterone (DHEA)	Boston Children's Hospital	marketed	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (indirect via peripheral conversion)
Agonist GnRH; estradiol Valerate; progesterone	Agonist GnRH; estradiol Valerate; progesterone	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Hormone combination therapy; GnRH agonist with steroid hormones	GnRH receptor; estrogen receptor; progesterone receptor
Vitamin D: liquid form, start monthly	Vitamin D: liquid form, start monthly	University Hospital, Basel, Switzerland	marketed	Vitamin/steroid hormone	Vitamin D receptor (VDR)
Vitamin D: liquid form, start weekly	Vitamin D: liquid form, start weekly	University Hospital, Basel, Switzerland	marketed	Vitamin/steroid hormone	Vitamin D receptor (VDR)
Vit D	Vit D	Al-Balqa Applied University	marketed	Vitamin/Steroid hormone	Vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Steroid hormone class)

Beth Israel Deaconess Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Progesterone Lozenges — Competitive Intelligence Brief. https://druglandscape.com/ci/progesterone-lozenges. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab